Therapeutic effects of antileukotrienes in children with moderate-severe persistent asthma;Efectos terapéuticos de un antileucotrieno en niños con asma persistente moderada-grave

Revista Alergia Mexico

Volumn 51, Issue 6, 2004, Pages 206-209

  Cuevas Hernández, María Magdalena ^a,b   Arias Hernández, Rosa María ^a  

^a Servicio de Alergología   (Cuba)

^b Plaza de la Revolución   (Cuba)

Author keywords

Antileukotrienes; Asthma; Zafirlukast

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; ZAFIRLUKAST; CORTICOSTEROID; TOLUENESULFONIC ACID DERIVATIVE;

ADOLESCENT; ARTICLE; ASTHMA; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION; MALE; MIGRAINE; RASH; SCHOOL CHILD; TREATMENT OUTCOME; CHILD; CLINICAL TRIAL; DRUG COMBINATION; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST;

ADOLESCENT; ADRENAL CORTEX HORMONES; ASTHMA; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; LEUKOTRIENE ANTAGONISTS; LIVER FUNCTION TESTS; MALE; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 17844370810     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Scorzo G, Giorcelli L. Asma bronquial. Medicina (Buenos Aires) 2000;60(Supl 1):100-8.
2. National Heart, Lung and Blood Institute. National Institute of Health. International Consensus Report on Diagnosis and Management of Asthma. NIH pub no 92-3091, Bethesda: US Departament of Health and Human Services, 1992.
3. Carreño-Hernández MC, Ferreiro-Álvarez MJ. Uso de antileucotrienos en el Asma. Inf Ter Sist Nac Salud 2002;26:152-7.
4. rd ed. Boston: Littl Brown, 1993;pp:1154-66.
5. Mazzei JA. Asma en el segundo milenio. Medicina (Buenos Aires) 2000;60(Supl 1):2-5.
6. Mullol J, Picado C. Inflamación en el asma: interacciones celulares y mediadores. Arch Bronconeumol 2001;37(Supl 3):2-8.
7. Rojas-Ramos E, Martínez-Jiménez NE. Teoría Th2 en Alergia. Rev Alergia México 1999;46(3):83-86.
8. Bermudes UC. Antileucotrienos. Alergia Asma e Inmunología Pediátrica 2000;9(6):200-5.
9. Plaza V. Antileucotrienos: historia, tipos y situación actual en el tratamiento del asma. Arch Bronconeumol 2001;37(Supl 3):25-29.
10. Dunn CJ, Goa KL. Zafirlukast an update of its pharmacology and therapeutic efficacy in asthma. Drugs 2001;61(2):285-315.
11. McGill KA, Busse WW. Zileuton. Lancet 1996;348:519-24.
12. Zafirlukast-Accolate® (Zeneca Farma). http://www.cof.es/pam221/ n_prod/zafir.htm
13. Lipworth BJ. Leukotriene-receptor antagonista. Lancet 1999;353:57-62.
14. García ML, Schuter A. New perspectives for asthma treatment antileukotriene drugs. Pediatr Allergy Immunol 1999;10:77-88.
15. Owens CA, Grundy GW. Focus on Zileuton: first FDA-approved agent of a new class of drug-5-lipoxygenase inhibitors the management of Asthma. Formulary 1997;32:455-71.
16. Guidelines for the diagnosis and management of asthma. Global Initiative for Asthma NHLBI and WHO. Publication no 97-4051, revised NIH publication no 96-3659-B (noviembre 1998). Bethesda 1997-1998.
17. National Institutes of Health. Global Strategy for Asthma Management and Prevention. Revised 2002. Disponible en URL: http://www.gjnasthma.com
18. Investigadores vinculados al departemento de inmunología del Hospital Victoria Royal de la ciudad de Montreal (Canadá). Beneficios del Zafirlukast en pacientes con asma leve y moderada. Ann Intern Med 1996;126:177-83.
19. Salazar I. El asma grave exige terapia combinada que bloquee la doble via. http://www.diariomedico.com octubre 2003, 1-2.
20. Virchow J, Prasse A, Naya I, Summerto L, Harris A. Zafirlukast improves asthma control in patients receiving high doses inhaled corticosteroids. Am J Respir Crit Core Med 2000;162:178-585.